**Supplemental Table 1 - Best standard of care administered to ALSYMPCA patientsa**   
**(ITT Population; N = 921)**

|  |  |  |
| --- | --- | --- |
| **BSoC Treatment** | **Radium-223 *n* = 614** | **Placebo**  ***n* = 307** |
| Patients with at least 1 concomitant medication,**a** *n* (%) | 599 (98) | 302 (98) |
| Patients with at least 1 cancer-related concomitant medication**,a** *n* (%) | 559 (91) | 287 (94) |
| **Concomitant medicationsa administered to ≥50% of patients in either treatment group, by drug class** | | |
| Drugs for peptic ulcer/gastrointestinal reflux disease, *n* (%) | 323 (53) | 182 (59) |
| Anti-inflammatory, anti-rheumatic, or nonsteroidal anti-inflammatory drugs, *n* (%) | 314 (51) | 172 (56) |
| Corticosteroids for systemic use, *n* (%) | 366 (60) | 220 (72) |
| Other analgesics and antipyretics, *n* (%) | 380 (62) | 196 (64) |
| Opioids, *n* (%) | 455 (74) | 241 (79) |
| Hormones and related agents, *n* (%) | 505 (82) | 259 (84) |
| **Cancer-related concomitant medications, a by drug class** | | |
| Cytotoxic antineoplastic agents, *n* (%) | 85 (14) | 52 (17) |
| Hormone antagonists, *n* (%) | 87 (14) | 70 (23) |
| Hormones and related agents, *n* (%) | 505 (82) | 259 (84) |
| Corticosteroids, *n* (%) | 263 (43) | 148 (48) |
| Drugs affecting bone structure and mineralization, *n* (%) | 262 (43) | 132 (43) |
| Immunostimulants, *n* (%) | 1 (<1) | 0 |
| Immunosuppressants, *n* (%) | 1 (<1) | 0 |

BSoC = best standard of care.

**a**From first injection of study drug to 12 weeks after the last dose.